10/07/22
Miami-Base Clinical Trials Company Tests First Drug for People Who Overuse Marijuana
Segal Trials, a privately held network of clinical research sites throughout South Florida, announced it will conduct a Phase 2B study to investigate a new drug, AEF0117-202, created by Aelis Farma to treat cannabis use disorder.
08/30/22
Segal Trials To Test Mind Medicine, Inc.’s MM-120 LSD-Based Drug In Phase II Human Trial
Segal Trials, a privately held network of clinical research sites throughout South Florida, announced its investigators will be the first in the nation to conduct a Phase II clinical trial to investigate an optimized LSD drug, MM-120, for the treatment of Generalized Anxiety Disorder.
08/23/22
Segal Trials Plays Pivotal Role In Karuna Therapeutics Submitting New Drug Application to the U.S. Food & Drug Administration (FDA)
Segal Trials, a privately held network of clinical research sites throughout South Florida has concluded a phase 3 EMERGENT-2 trial with Karuna Therapeutics. The study focused on evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline-trospium), in adults with schizophrenia.
06/12/20
Segal Trials Connecting People, Processes and Purpose in Commitment to Mental Health Awareness Month
Segal Trials, a privately held network of research sites throughout South Florida and South Carolina conducting Phase I-IV trials, commemorated Mental Health Awareness Month and Clinical Trial Awareness Day with key initiatives celebrating the individuals who help advance public health.
02/29/20
Segal Trials Screens its First Patient in a study of Psilocybin for Major Depressive Disorder
Over the years, Segal Trials has grown into one of the premier, privately held clinical trial sites in the U.S., with six sites located in South Florida and Charleston, South Carolina focusing on mental health and women’s health; and has been awarded groundbreaking studies such as the use of Psilocybin as a treatment for MDD in the study PSIL201 (ClinicalTrials.gov Identifier: NCT03866174).
10/23/19
Segal Trials Acquires New Studies with Schedule 1 DEA License and Continues to Expand its Network of Inpatient and Outpatient Facilities
Segal Trials, a privately held network of research sites throughout South Florida and South Carolina conducting Phase I–IV trials, has been named one of seven sites to begin a Phase II study of psilocybin—a psychedelic prodrug compound—for major depressive disorder (MDD). Segal Trials holds a Schedule 1 DEA License and will be taking part in Usona Institute’s Phase II PSIL201 study investigating the safety and efficacy of psilocybin for MDD.
07/11/19
Segal Trials Celebrates Medical Heroes
Segal Trials Summer Kick-Off Event Celebrated Those Who are Moving the Medical Community Forward with New, Innovative Treatments for Mental Health and Women’s Health.
05/28/19
Segal Trials Launched Miami Lakes Medical Research, Early Phase & Inpatient/Outpatient Site
Segal Trials is excited to announce the official launch of Miami Lakes Medical Research, its newest research site in Miami Lakes, Florida. The state-of-the-art, dedicated clinical research facility specializes in early phase, inpatient and outpatient trials and focuses on patients with psychiatric, neurologic and general medical conditions.
01/23/19
FDA permits marketing of first test to aid in the diagnosis of a sexually-transmitted infection known as Mycoplasma genitalium
Segal’s own, Dr. Steven Chavoustie, is proud to have worked on the clinical trials that brought this medication to market. The U.S. Food and Drug Administration today permitted marketing of a new test to aid in the diagnosis of a sexually-transmitted infection (STI) called Mycoplasma genitalium (M. gen.). This is the first test authorized by the FDA to test for the M. gen. bacterium, which is associated with inflammation of the urethra (non-gonococcal urethritis) in men and inflammation of the cervix (cervicitis) and infection of the reproductive organs (pelvic inflammatory disease) in women.
08/08/18
Segal Trials Hosts Clinical Trial Awareness Event in Collaboration with CISCRP at a Major League Baseball Game
In an effort to raise clinical trial awareness and promote the importance of diversity in clinical trials, Segal Trials and The Center for Information and Study on Clinical Research Participation (CISCRP) co-hosted a clinical trial awareness event at a Major League Baseball arena.
05/08/18
Segal Trials Fundraises for the National Alliance on Mental Illness through a Social Media Campaign
In an effort to support local mental health advocacy groups, Segal Trials, a network of clinical research sites, ran a Facebook fundraising campaign for the Miami-Dade and Broward County affiliates of NAMI, the National Alliance on Mental Illness.
04/25/18
Alkahest Announces Initiation of Phase 2 Clinical Trial of GRF6019 in Alzheimer’s Disease
Segal Trials is proud to be one of the nine sites working on this novel & cutting edge study for those suffering from Alzheimer’s Disease.
“The initiation of this study represents a significant milestone for Alkahest, and reflects our commitment to developing innovative therapies to treat this devastating disease,” said Karoly Nikolich, President and Chief Executive Officer of Alkahest.
04/03/18
Segal Trials announces its newest initiative toward raising clinical trial awareness through its partnership with Greater Gift (GG)
Greater Gift’s mission is to advance global health and highlight the greater good of clinical trial participation by gifting a vaccine to a child in need in honor of each clinical trial volunteer. The vision of GG…
02/27/18
Vice President of Segal Trials Appointed as a NAMI Broward County Board Member
Bonnie Segal, Vice President and Co-Founder of Segal Trials, has been appointed as a NAMI (National Alliance on Mental Illness) Broward County Board Member. NAMI is the nation’s largest grassroots mental health organization dedicated to building better lives for the millions of Americans affected by mental illness.
7/11/17
Segal Trials Announces Company Name Change to Segal Trials
After 19 years, Segal Trials proudly announces its corporate name change to Segal Trials effective, July 11, 2017.
7/6/17
Dr. Rishi Kakar of Segal Trials Partners with INC Research in the Launch of the Psychiatry Catalyst Site Network
Segal Trial’s, Dr. Rishi Kakar, is proud to be a part of INC Research’s elite group of sites that was selected to participate in the initial launch of the Psychiatry Catalyst Site Network. The Psychiatry Catalyst Site Network therapeutically-aligned network offers high-performing sites in psychiatry research the opportunity to conduct more trials and enhances high quality delivery for biopharmaceutical customers.
5/19/17
Segal Trials Launches New Employee Recognition Program
In honor of Clinical Trials Awareness Day, Segal Trials has implemented a new employee recognition program, the Diamond Club, to acknowledge their greatest asset – their staff.
3/28/17
Dr. Steven Chavoustie of Segal Trials Listed as an Author on Research Paper
Segal Trials’ Dr. Steven Chavoustie helped to author the research paper, “Experts explore the state of bacterial vaginosis and the unmet needs facing women and providers,” recently published in the International Journal of Gynecology & Obstetrics, the official publication of the International Federation of Gynecology and Obstetrics (FIGO).
2/24/17
Curemark Announces Further Expansion of Clinical Sites For Its Phase 3 Clinical Trial for Children with Autism
Curemark, LLC announced today that the Blüm Study, a Phase 3 clinical trial to evaluate the safety and efficacy of CM-AT in children aged 3-8 with Autism, is now enrolling at three new sites. These new sites are in addition to the 30 clinical sites already enrolling children across the United States….
9/20/16
Segal Trials Takes Essential Step to Reduce Duplicate Enrollment In Clinical Trials
Segal Trials has chosen Verified Clinical Trials (VCT), the global clinical trial database registry utilizing biometric fingerprint technology, to counter attempts at duplicate enrollment in clinical trial research and improve the safety of research volunteers and data quality…
5/11/16
Mental Health Organizations Work Together to Educate, Support and Encourage People to Take Action against an Illness that affects Millions of People Every Year
People are diagnosed with mental illness every day. Statistics alone would alarm anyone unfamiliar with the condition; a rare occurrence, as mental disorders affect one in four people…
1/8/16
Segal Trials Proudly Participates in Phase 3 Efficacy Trial of Long-acting Treatment Opioid Dependence
Segal Trials has three Principal Investigators currently participating in Braeburn Pharmaceuticals and Camurus’ Phase 3 efficacy Trial of Long-acting Treatment for Opioid …
1/8/16
Segal Trials Recognized as Top Fundraiser for Namiwalk Broward County
Segal Trials was recently recognized as the top fundraiser at the annual NAMIWalk Broward County during NAMI Broward County’s Holiday Party, Volunteer Recognition and Walk…
1/6/16
Dr.Rishi Kakar of Segal Trials Listed as an Author on Research Paper
Segal Trials’ Dr. Rishi Kakar helped to author the research paper, “A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from…
